Evidence map›Paper›PMID 39847203›Full record

Observational studyBreast cancer research and treatment2025

A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2-negative advanced breast cancer.

Catherine Doyle, Ana Elisa Lohmann, Nayyer Iqbal, Jan-Willem Henning, Swati Kulkarni, Nadia Califaretti, John Hilton, Cristiano Ferrario, Nathaniel Bouganim, Mihaela Mates and 6 more

Erratum issued Registry-linked trialAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02753686 (Treatment of Canadian Men and Pre/Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy), which is not on this map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02753686 completednot on this map

Treatment of Canadian Men and Pre/Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy

Typeobservational_patient_registrySponsorNovartis PharmaceuticalsRan2016 to 2022Enrolled440ConditionsHR+ HER2- Men, Pre/Postmenopausal Advanced Breast CancerArmsEndocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Catherine DoyleHemato-Oncology, Centre Hospitalier Universitaire de Québec, Quebec City, QC, Canada.
Ana Elisa LohmannMedical Oncology, Western University, London, ON, Canada.
Nayyer IqbalMedical Oncology, Saskatchewan Cancer Agency, Saskatoon, SK, Canada.
Jan-Willem HenningMedical Oncology, Tom Baker Cancer Center, Calgary, AB, Canada.
Swati KulkarniMedical Oncology, Windsor Regional Cancer Center, Windsor, ON, Canada.
Nadia CalifarettiMedical Oncology, Grand River Regional Cancer Center, Kitchener, ON, Canada.
John HiltonMedical Oncology, The Ottawa Hospital Regional Cancer Centre, Ottawa, ON, Canada.
Cristiano FerrarioMedical Oncology, Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada.
Nathaniel BouganimMedical Oncology, McGill University Health Centre, Montreal, QC, Canada.
Mihaela MatesMedical Oncology, Cancer Centre of Southeastern Ontario at Kingston Health Sciences Centre, Kingston, ON, Canada.
Stephanie GuillemetteNovartis Pharmaceuticals Canada Inc., Montreal, QC, Canada.
Ricardo LeiteNovartis Pharmaceuticals Canada Inc., Montreal, QC, Canada.
Marc-Andre CaronNovartis Pharmaceuticals Canada Inc., Montreal, QC, Canada.
Francois ThireauTranslational Research in Oncology, Paris, France.
Andres MachadoTranslational Research in Oncology, Montevideo, Uruguay.
Stephen ChiaMedical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada. schia@bccancer.bc.ca.ORCID https://orcid.org/0000-0001-7070-4386

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeUnderstanding real-world treatment patterns and their effectiveness in HR + HER2- advanced breast cancer (aBC) in Canadian patients. PATIENT AND

methodsThis was a multi-center, observational, prospective cohort study including men and pre-/peri-/postmenopausal women with HR + HER2- aBC receiving endocrine therapy (ET) or ET + targeted therapy (ET + TT). The primary objective was duration of treatment (DOT) with ET and ET + TT. Sequence of therapies, treatment patterns, and Overall Survival (OS) were also evaluated.

resultsDOT was prolonged in patients receiving ET + TT compared to ET (median DOT: ET + TT 397 days vs ET 192 days; Log-Rank test p value < .0001; HR = 0.66; 95% CI; 0.52, 0.85). An extended DOT was observed in ET + CDK4/6i subgroup when compared to ET (median DOT: ET + CDK4/6i 601 days vs ET 192 days; Log-Rank test p value < .0001). This increase was statistically significant irrespective of line of therapy at baseline (1L: median DOT: ET + CDK4/6i: 649 days vs ET: 217 days, p value =  < .0001; 2L: median DOT: ET + CDK4/6i: 487 days vs ET: 203 days, p value = 0.0013; 3L: median DOT: ET + CDK4/6i: 597 days vs ET: 143 days therapy: p value = 0.0006). ET alone and ET + CDK4/6i were the most frequently administered therapies in both 1st (ET alone: 43.5% and ET + CDK4/6i: 43.3%) and 2nd lines (ET alone: 36.3% and ET + CDK4/6i: 24.6%). Among patients who received at least one CDK4/6i in 1st, 2nd, or 3rd line, CDK4/6i were mostly administered in 1st line (61.9%) and 2nd line (38.5%). CLINICALTRIALS: gov ID: NCT02753686; Registration Date:20-04-2016.

conclusionResults support current treatment recommendations of early introduction of CDK4/6i in HR + /HER2- aBC.

Indexed as

Antineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesAdultAgedAged, 80 and overCanadaFemaleHumansMaleMiddle AgedMolecular Targeted TherapyNeoplasm StagingProspective StudiesReceptors, EstrogenAntineoplastic Agents, HormonalERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneAdvanced breast cancerCDK4/6iPalbociclibReal-world evidenceRibociclibTreatment sequencing

Identifiers

PMID39847203
PMCPMC11930880

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.